Exelderm

Manufacturer
Journey Medical Corporation | DPT Laboratories, Ltd.
Effective date
2026-06-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
daily-update
Hydrated at
2026-06-11 05:11:44

Label at a glance#

ProductExelderm
Active ingredientSULCONAZOLE NITRATE
Label structure11 sections

Indications and uses

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few ...

Dosage and administration

A small amount of solution should be gently massaged into the affected and surrounding skin areas once or twice daily. Symptomatic relief usually occurs within a few days after starting EXELDERM (sulconazole nitrate) SOLUTION, 1.0%, and clinical improvement usually occurs within 1 week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 weeks. If sig...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(sulconazole nitrate, USP)
Solution, 1.0%

Rx only

For topical use only. Not for ophthalmic use.

DESCRIPTION

DESCRIPTION SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent intended for topical application. Sulconazole nitrate, USP, the active ingredient in EXELDERM SOLUTION, is an imidazole derivative with antifungal and antiyeast activity. Its chemical name is (±)-1-[2,4-dichloro-β-[(p-chlorobenzyl)-thio]-phenethyl] imidazole mononitrate and it has the following chemical structure:

Chemical StructureChemical Structure

Sulconazole nitrate, USP is a white to off-white crystalline powder with a molecular weight of 460.77. It is freely soluble in pyridine; slightly soluble in ethanol, acetone, and chloroform; and very slightly soluble in water. It has a melting point of about 130°C.

EXELDERM SOLUTION contains sulconazole nitrate, USP 10 mg/mL in a solution of propylene glycol, poloxamer 407, polysorbate 20, butylated hydroxyanisole, and purified water, with sodium hydroxide and, if necessary, nitric acid added to adjust the pH.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sulconazole nitrate is an imidazole derivative that inhibits the growth of the common pathogenic dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum,and Microsporum canis.It also inhibits the organism responsible for tinea versicolor, Malassezia furfur,and certain gram-positive bacteria.

A maximization test with sulconazole nitrate solution showed no evidence of irritation or contact sensitization.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum,and Microsporum canis;and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot).

Symptomatic relief usually occurs within a few days after starting EXELDERM SOLUTION and clinical improvement usually occurs within one week.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is contraindicated in patients who have a history of hypersensitivity to any of the ingredients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is for external use only. Avoid contact with the eyes. If irritation develops, the solution should be discontinued and appropriate therapy instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients should be told to use EXELDERM SOLUTION as directed by the physician, to use it externally only, and to avoid contact with the eyes.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies to determine carcinogenic potential have not been performed. In vitrostudies have shown no mutagenic activity.

Pregnancy

PREGNANCY SECTION

SPL UNCLASSIFIED SECTION

Sulconazole nitrate has been shown to be embryotoxic in rats when given in doses 125 times the human dose (in mg/kg). The drug at this dose given orally to rats also resulted in prolonged gestation and dystocia. Several females died during the perinatal period, most likely due to labor complications. Sulconazole nitrate was not teratogenic in rats or rabbits at oral doses of 50 mg/kg/day.

There are no adequate and well-controlled studies in pregnant women. Sulconazole nitrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sulconazole nitrate is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of EXELDERM SOLUTION, 1.0%, did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

There were no systemic effects and only infrequent cutaneous adverse reactions in 370 patients treated with sulconazole nitrate solution in controlled clinical trials. Approximately 1% of these patients reported itching and 1% burning or stinging. These complaints did not usually interfere with treatment.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of solution should be gently massaged into the affected and surrounding skin areas once or twice daily.

Symptomatic relief usually occurs within a few days after starting EXELDERM (sulconazole nitrate) SOLUTION, 1.0%, and clinical improvement usually occurs within 1 week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 weeks.

If significant clinical improvement is not seen after 4 weeks of treatment, an alternate diagnosis should be considered.

HOW SUPPLIED

HOW SUPPLIED SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a clear, slightly viscous, colorless to slightly yellow liquid with a slight characteristic odor. It is supplied as follows:

             30 mL plastic bottle – NDC 69489-721-30

Avoid excessive heat, above 40° C (104° F), and protect from light.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


JOURNEY ®
MEDICAL CORPORATION

Manufactured for:
Journey Medical Corp.
Scottsdale, AZ 85258
www.JMCderm.com



141112               Revised March 2021

Principal Display Panel – 30 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 69489-721-30

Exelderm®

(sulconazole
nitrate, USP)
Solution,1.0%

30 mL

Rx only

For topical use only.

Not for ophthalmic use.

JOURNEY

MEDICAL CORPORATION

Principal Display Panel – 30 mL Carton LabelPrincipal Display Panel – 30 mL Carton Label

Principal Display Panel – 30 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Exelderm®​    NDC 69489-721-30

(sulconazole nitrate, USP)
Solution,1.0%

Rx only

For topical use only.

Not for ophthalmic use.

30 mL

Principal Display Panel – 30 mL Bottle LabelPrincipal Display Panel – 30 mL Bottle Label

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
312a1339-2d03-1da9-f090-a47730c5330aProduct name120140508
a4a028cc-e548-445b-8dc3-ebf42e7603dbProduct name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
69489-721-30ML - Milliliter69489-72132a82580-19f2-4d48-af79-e4b0ce7355bb12020-02-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
69489-72169489-721-30, 69489-721-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32022-11-08full-release2026-05-31 20:44:53

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018738-001EXELDERMSULCONAZOLE NITRATE1%SOLUTION / TOPICALRLD1985-08-30

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-30c2088c7a36db…
2026-09-14 22:38:342026-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-3084e616aacf4f…
2026-08-18 06:07:402026-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3087673890dc5c…
2021-03-12 10:30 UTC2021-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303f01610625f2…
2019-09-15 20:21 UTC2019-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30b00525d2431f…
2019-07-19 19:46 UTC2019-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303f0d92c62455…
2023-05-13 08:27 UTC2023-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30053a50430f4f…
2023-01-26 05:58 UTC2023-01N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ExeldermSULCONAZOLE NITRATEJourney Medical Corporation5b73e83e-8d3c-4d96-b4f6-9f854430add82026-06-08Adverse reactionsExact identifier
ndc (package): 69489-721-05
ndc (package): 69489-721-30
ndc (product): 69489-721
ndc11 (package): 69489072105
ndc11 (package): 69489072130
spl id: 53b92932-d626-2d66-e063-6294a90a8f6a
spl set id: 5b73e83e-8d3c-4d96-b4f6-9f854430add8

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.